ARIAD to Present at the Jefferies 2016 Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
ARIAD Pharma (ARIA) Announces Completion of European Ops Sale to Incyte (INCY)
June 2, 2016 7:36 AM EDTARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced that it has completed the sale of its European operations to Incyte Corporation and entered into the previously announced license agreement for Incyte to exclusively license Iclusig... More
Incyte (INCY) Europe Granted Exclusive Iclusig Development, Commercialization Rights in EU, Additional Countries (ARIA)
June 1, 2016 4:13 PM EDTIncyte (NASDAQ: INCY) disclosed the following on Wednesday:
Item 1.01 Entry Into a Material Definitive Agreement.
On June 1, 2016, an Amended and Restated Buy-in License Agreement was entered into by ARIAD Pharmaceuticals, Inc. (ARIAD), ARIAD Pharmaceuticals (Europe) S.a.r.l. (ARIAD Europe), and Incyte Corporation (Incyte), as guarantor (the License Agreement). ARIAD Europe is one of the entities that became owned by Incyte Europe S.Ã .r.l. (Incyte Europe), a wholly-owned subsidiary of Incyte, upon the closing of the Acquisition described under Item 2.01 below. ARIAD Europe and Incyte Europe are collectively referred to in the remainder of... More
